| Literature DB >> 32611399 |
Heyan Wu1,2, Zhengkun Xia3, Chunlin Gao4, Pei Zhang1, Xiao Yang1, Ren Wang5, Meiqiu Wang1, Yingchao Peng1.
Abstract
BACKGROUND: The 2016 Oxford Classification's MEST-C scoring system predicts outcomes in adults with IgA nephropathy (IgAN), but it lacks tremendous cohort validation in children with IgAN in China. We sought to verify whether the Oxford classification could be used to predict the renal outcome of children with IgAN.Entities:
Keywords: Children; IgA nephropathy; Oxford classification; Renal outcome
Year: 2020 PMID: 32611399 PMCID: PMC7329550 DOI: 10.1186/s12882-020-01913-7
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Baseline and follow-up characteristics (n = 1243)
| At renal biopsy | Values at renal biopsy |
|---|---|
| Male, % | 68 |
| Age, years | 14 ± 4 |
| Duration from onset to renal biopsy (months) | 12.0 (0.8,96.5) |
| eGFR, ml/min per 1.73 m2 | 102 ± 20 |
| MAP, mmHg | 89 ± 16 |
| Proteinuria, g/day per 1.73m2 | 0.6 (0.3–1.4) |
| Follow-up parameters | Values during follow-up |
| Length of follow-up, years | 7.2 (4.6–11.7) |
| RASB, % | 70 |
| Any immunosuppression, % | 64 |
| GC, % | 45 |
| GC + IS, % | 19 |
| Combined event, % | 14 |
| ESRD, % | 6.6 |
| 50% reduction in initial eGFR,% | 7.2 |
Values are expressed as mean ± SD; medians (interquartile ranges), or percentages
Abbreviations: eGFR Estimate glomerular filtration rate, MAP Mean arterial pressure, RASB Renin angiotensin aldosterone system blockade, GC Glucocorticoid, IS Other immunosuppressant, ESRD End-stage of renal disease
Pathological findings at the time of biopsy in children with IgA nephropathy (n = 1243)
| Pathology findings | Values at renal biopsy |
|---|---|
| The number of glomeruli per biopsy | 20.4 ± 4.7 |
| MEST-C score | % of total biopsies |
| M1 | 29 |
| E1 | 35 |
| S1 | 37 |
| T1 | 23 |
| T2 | 4.3 |
| C1 | 44 |
| C2 | 4.6 |
| Deposition site of immunoglobulins | % of total biopsies |
| Pure-mesangium | 68 |
| Mesangium+ capillary loop | 32 |
| Immunoglobulins deposits | % of total biopsies |
| Glomerular IgG deposition | 25 |
| Glomerular IgM deposition | 44 |
| Glomerular C3 deposition | 84 |
| Glomerular C4 deposition | 1.1 |
| Intensity of IgA deposits a | % of total biopsies |
| 1+ | 5.6 |
| 2+ | 13 |
| 3+ | 81 |
Values are expressed as mean ± SD or number (percentage); The intensity of IgA deposits as determined via immunofluorescence microscopy was graded semi-quantitatively on a scale from 0 to 3+, where 0 no, 1 + = slight, 2 + = moderate, and 3 + = intense
Abbreviations: M1 Mesangial hypercellularity>0.5, E1 Presence of endocapillary hypercellularity, S1 Presence of segmental glomerulosclerosis, T1 Tubular atrophy/ interstitial fibrosis 26–50% of cortical area, T2 Tubular atrophy/interstitial fibrosis≥50% of cortical area, C1 Crescents in at least one but < 25% of glomeruli, C2 Crescents in more than 25% of glomeruli
Fig. 1Distribution of the percentage of glomeruli with crescents in biopsies with any crescents. Crescents were present in 599(48%) of 1243 total biopsies
Comparison of all kinds of lesions with different time of onset to renal biopsy (n = 1243)
| Variables | Time from onset to renal biopsy | χ2 | ||
|---|---|---|---|---|
| ≤ 12 months | >12 months | |||
| M0/M1 | 449/172 | 433/189 | 1.1 | 0.296 |
| E0/ E1 | 411/210 | 401/221 | 0.4 | 0.525 |
| S0/ S1 | 554/67 | 235/387 | 354.5 | <0.001 |
| T0/ T1/ T2 | 595/21/5 | 315/259/48 | 323.3 | <0.001 |
| C0/ C1/ C2 | 506/104/11 | 138/438/46 | 437.6 | <0.001 |
Abbreviations: M0 Mesangial hypercellularity≤0.5, M1 Mesangial hypercellularity>0.5, E0 Absence of endocapillary hypercellularity, E1 Presence of endocapillary hypercellularity; S0 absence of segmental glomerulosclerosis, S1 Presence of segmental glomerulosclerosis, T0 Tubular atrophy/ interstitial fibrosis 0–25% of cortical area, T1 Tubular atrophy/ interstitial fibrosis 26–50% of cortical area, T2 Tubular atrophy/interstitial fibrosis≥50% of cortical area, C0 Absence of crescents, C1 Crescents in at least one but < 25% of glomeruli, C2 Crescents in more than 25% of glomeruli
Linear Regression Analysis of Oxford Classification and Clinical Indicators at Renal Biopsy
| Clinical indicators | MAP (mmHg) | eGFR (ml/min/1.73m2) | Proteinuria (g/day/1.73m2) | |||
|---|---|---|---|---|---|---|
| R | R | R | ||||
| M1 | 0.342 | <0.001 | 0.044 | 0.133 | 0.569 | <0.001 |
| E1 | 0.338 | <0.001 | −0.331 | 0.389 | 0.527 | <0.001 |
| S1 | 0.541 | 0.042 | −0.744 | 0.007 | 0.604 | <0.001 |
| T1–2 | 0.532 | <0.001 | −0.578 | <0.001 | 0.689 | <0.001 |
| C1–2 | 0.549 | 0.008 | −0.447 | <0.001 | 0.447 | <0.001 |
Linear Regression results are results from separate models for each independent variable
Abbreviations: MAP Mean arterial blood pressure, eGFR Estimate glomerular filtration rate, M1 Mesangial hypercellularity>0.5, E1 Presence of endocapillary hypercellularity, S1 Presence of segmental glomerulosclerosis, T1 Tubular atrophy/ interstitial fibrosis 26–50% of cortical area, T2 Tubular atrophy/interstitial fibrosis≥50% of cortical area, C1 Crescents in at least one but < 25% of glomeruli, C2 Crescents in more than 25% of glomeruli
Fig. 2Renal survival according to pathological variables. a Effect of the presence of mesangial hypercellularity on survival from a combined event in all patients. b Effect of the presence of endocapillary hypercellularity on survival from a combined event in all patients. c Effect of the presence of segmental sclerosis on survival from a combined event in all patients. d Effect of the presence of interstitial fibrosis/tubular atrophy on survival from a combined event in all patients. e Effect of the presence of cellular/fibrocellular crescents on survival from a combined event in all patients
Factors at biopsy influencing renal outcome from ESRD or 50% drop in eGFR by univariate and multivariate Cox regression
| Risk factors | Univariate Cox Regression | Multivariate Cox Regression |
|---|---|---|
| HR(95%CI) | HR(95%CI) | |
| Mesangial hypercellularity | ||
| M0 | 1 | |
| M1 | 1.8 (1.3 ~ 2.3) | |
| 0.115 | ||
| Endocapillary hypercellularity | ||
| E0 | 1 | |
| E1 | 1.4 (0.9 ~ 2.1) | |
| 0.326 | ||
| Segmental glomerulosclerosis | ||
| S0 | 1 | 1 |
| S1 | 3.5 (2.3 ~ 5.3) | 2.7 (1.8 ~ 4.2) |
| <0.001 | <0.001 | |
| Tubular atrophy/interstitial fibrosis | ||
| T0 | 1 | 1 |
| T1 or T2 | 2.6 (2.1 ~ 3.3) | 6.6 (3.9 ~ 11.3) |
| <0.001 | <0.001 | |
| Crescent | ||
| C0 | 1 | 1 |
| C1 or C2 | 2.1 (1.5 ~ 2.8) | 1.8 (1.2 ~ 2.5) |
| <0.001 | 0.212 | |
Univariate Cox Regression model: unadjusted. Multivariate Cox Regression model: adjusted for initial eGFR, initial mean arterial pressure, and initial proteinuria
Abbreviations: CI Confidence interval, HR Hazard ratio, M0 Mesangial hypercellularity≤0.5, M1 Mesangial hypercellularity>0.5, E0 Absence of endocapillary hypercellularity, E1 Presence of endocapillary hypercellularity, S0 Absence of segmental glomerulosclerosis, S1 Presence of segmental glomerulosclerosis, T0 Tubular atrophy/ interstitial fibrosis 0–25% of cortical area, T1 Tubular atrophy/ interstitial fibrosis 26–50% of cortical area, T2 Tubular atrophy/interstitial fibrosis≥50% of cortical area, C0 Absence of crescents, C1 Crescents in at least one but < 25% of glomeruli, C2 Crescents in more than 25% of glomeruli
Fig. 3Predictive value of mesangial hypercellularity, endocapillary hypercellularity and cellular/fibrocellular crescents between immunosuppressive and without immunosuppressive groups. a Effect of the presence of mesangial hypercellularity on survival from a combined event in patients without immunosuppression. b Effect of the presence of mesangial hypercellularity on survival from a combined event in patients with immunosuppression. c Effect of the presence of endocapillary hypercellularity on survival from a combined event in patients without immunosuppression. d Effect of the presence of endocapillary hypercellularity on survival from a combined event in patients with immunosuppression. e Effect of the presence of cellular/fibrocellular crescents on survival from a combined event in patients without immunosuppression. f Effect of the presence of cellular/fibrocellular crescents on survival from a combined event in patients with immunosuppression